Analytical Data
-
Gene name
PLS1
- Application
-
Alternative Names
I-plastin; Fimbrin; Intestine-specific plastin
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q14651
-
Expression Region
Thr108~Lys380
-
Molecular Weight
34kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PLS1, or plastin 1, is an actin-binding protein that plays a critical role in the regulation of cytoskeletal dynamics and cellular functions. Research into PLS1 has gained prominence due to its involvement in various cellular processes, including cell adhesion, migration, and shape maintenance, which are essential for proper tissue function and organismal development. Abnormalities in PLS1 expression or function have been linked to several pathological conditions, including cancer metastasis and autoimmune diseases. Understanding the molecular mechanisms by which PLS1 interacts with the cytoskeleton can provide insights into its role in these diseases, as well as its potential as a therapeutic target. Furthermore, as a recombinant protein, PLS1 is of interest for biotechnological applications and offers opportunities for drug development, particularly in the context of modulating actin dynamics in therapeutic settings. Research into the recombinant expression and functional characterization of PLS1 is crucial for elucidating its biological significance and potential utility in clinical applications.
